The board of CAREIUM AB's (publ), org. no. 559121–5875, ("the Company") proposal regarding authorisation to resolve on to sell of the company's own shares

The board of CAREIUM AB (publ), org. no. 559121–5875, (the Company) proposes that the Annual General Meeting decides to authorize the Board to make a decision on the transfer of the Company's own shares, in essence in accordance with the following:

The authorization may be utilized on one or several occasions, until the annual general meeting in 2023.

- 1. Transfer may be affected by no more than all of the company's own shares held by the Company at the time of the board's transfer decision
- 2. Transfer may take place with deviation from the shareholders' preferential rights.
- 3. Transfer may be made against cash payment through sale on Nasdaq First North Growth Market, at a price within the prevailing price range at any time, which means the interval between the highest bid price and the lowest selling price at the time of sale.
- 4. Transfer may be made as payment of all or part of the purchase price in connection with the acquisition of a company or business or part of a company or business. Transfer in connection with company acquisitions may be made to one of the Board assessed market value. Payment for transferred shares in connection with company acquisitions may be capital contributed in kind or by set-off.
- 5. The board may decide on other conditions for the transfer.

It can be noted that Information about how many shares the Company holds at the time of the annual general meeting will be reported at the annual general meeting.

The purpose of the authorization is to enable acquisition financing through the use of own shares.

Transfer of own shares within the framework of incentive programs introduced by the Company shall be carried out with the support of the annual general meeting's decision regarding each such incentive program and thus do not fall within the proposed authorization.

If a transfer is not made as described above, the Company shall have the right to decide on redemption of the shares by reducing the company's share capital without repayment to the shareholders.

A resolution in accordance with the proposal shall only be valid where supported by not less than twothirds of both the votes cast and the shares represented at the annual general meeting.

Malmö, March 2022 CAREIUM AB (publ) The Board of Directors